601 related articles for article (PubMed ID: 25986385)
21. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.
Yu EW; Bauer SR; Bain PA; Bauer DC
Am J Med; 2011 Jun; 124(6):519-26. PubMed ID: 21605729
[TBL] [Abstract][Full Text] [Related]
22. Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.
Vangala C; Niu J; Lenihan CR; Mitch WE; Navaneethan SD; Winkelmayer WC
Clin J Am Soc Nephrol; 2018 Oct; 13(10):1534-1541. PubMed ID: 30262672
[TBL] [Abstract][Full Text] [Related]
23. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study.
Abtahi S; Driessen JHM; Burden AM; Souverein PC; van den Bergh JP; van Staa TP; Boonen A; de Vries F
Ann Rheum Dis; 2021 Apr; 80(4):423-431. PubMed ID: 33310727
[TBL] [Abstract][Full Text] [Related]
24. Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study.
Freedberg DE; Lamousé-Smith ES; Lightdale JR; Jin Z; Yang YX; Abrams JA
Clin Infect Dis; 2015 Sep; 61(6):912-7. PubMed ID: 26060292
[TBL] [Abstract][Full Text] [Related]
25. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.
Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
Osteoporos Int; 2017 May; 28(5):1587-1595. PubMed ID: 28083667
[TBL] [Abstract][Full Text] [Related]
26. Proton Pump Inhibitors, But Not H2-receptor Antagonists, Are Associated With Incident Fractures Among Kidney Transplant Recipients.
Lyu B; Jorgenson MR; Hansen KE; Djamali A; Astor BC
Transplantation; 2020 Dec; 104(12):2609-2615. PubMed ID: 32058466
[TBL] [Abstract][Full Text] [Related]
27. Acid-suppressive medications and risk of bone loss and fracture in older adults.
Yu EW; Blackwell T; Ensrud KE; Hillier TA; Lane NE; Orwoll E; Bauer DC
Calcif Tissue Int; 2008 Oct; 83(4):251-9. PubMed ID: 18813868
[TBL] [Abstract][Full Text] [Related]
28. Association Between Proton Pump Inhibitor Use and Risk of Fracture in Children.
Wang YH; Wintzell V; Ludvigsson JF; Svanström H; Pasternak B
JAMA Pediatr; 2020 Jun; 174(6):543-551. PubMed ID: 32176276
[TBL] [Abstract][Full Text] [Related]
29. Early Acid Suppression Therapy Exposure and Fracture in Young Children.
Malchodi L; Wagner K; Susi A; Gorman G; Hisle-Gorman E
Pediatrics; 2019 Jul; 144(1):. PubMed ID: 31175146
[TBL] [Abstract][Full Text] [Related]
30. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study.
Moberg LM; Nilsson PM; Samsioe G; Borgfeldt C
Maturitas; 2014 Aug; 78(4):310-5. PubMed ID: 24958166
[TBL] [Abstract][Full Text] [Related]
31. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies.
Tran KT; McMenamin ÚC; Hicks B; Murchie P; Thrift AP; Coleman HG; Iversen L; Johnston BT; Lee AJ; Cardwell CR
Aliment Pharmacol Ther; 2018 Jul; 48(1):55-64. PubMed ID: 29741272
[TBL] [Abstract][Full Text] [Related]
32. Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Proton Pump Inhibitors, or Metoclopramide: A Population-Based Nested Case-Control Study.
Arana A; Johannes CB; McQuay LJ; Varas-Lorenzo C; Fife D; Rothman KJ
Drug Saf; 2015 Dec; 38(12):1187-99. PubMed ID: 26350642
[TBL] [Abstract][Full Text] [Related]
33. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates.
de Vries F; Cooper AL; Cockle SM; van Staa TP; Cooper C
Osteoporos Int; 2009 Dec; 20(12):1989-98. PubMed ID: 19333676
[TBL] [Abstract][Full Text] [Related]
34. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
[TBL] [Abstract][Full Text] [Related]
35. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study.
Dublin S; Walker RL; Jackson ML; Nelson JC; Weiss NS; Jackson LA
Pharmacoepidemiol Drug Saf; 2010 Aug; 19(8):792-802. PubMed ID: 20623507
[TBL] [Abstract][Full Text] [Related]
36. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency.
Lam JR; Schneider JL; Quesenberry CP; Corley DA
Gastroenterology; 2017 Mar; 152(4):821-829.e1. PubMed ID: 27890768
[TBL] [Abstract][Full Text] [Related]
37. Beyond uncertainty: Negative findings for the association between the use of proton pump inhibitors and risk of dementia.
Park SK; Nam JH; Lee H; Chung H; Lee EK; Shin JY
J Gastroenterol Hepatol; 2019 Dec; 34(12):2135-2143. PubMed ID: 31145825
[TBL] [Abstract][Full Text] [Related]
38. Associations between Proton Pump Inhibitor and Histamine-2 Receptor Antagonist and Bone Mineral Density among Kidney Transplant Recipients.
Lyu B; Hansen KE; Jorgenson MR; Astor BC
Am J Nephrol; 2020; 51(6):433-441. PubMed ID: 32485707
[TBL] [Abstract][Full Text] [Related]
39. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
Kendler DL; Marin F; Geusens P; López-Romero P; Lespessailles E; Body JJ; Minisola S
Bone; 2020 Jan; 130():115113. PubMed ID: 31654779
[TBL] [Abstract][Full Text] [Related]
40. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
